Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor ...

From 2020 to 2023, the number of individuals ages 12 to 25 years who received a prescription for the diabetes or weight-loss ...

Semaglutide medications including Ozempic and Wegovy have been shown to reduce kidney failure risk and the risk of death ...

No Ozempy for Missy G. The post Melissa Gorga Claims She’s Only RHONJ Castmate Not on Ozempic appeared first on Reality Tea.

Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating ...

Zealand Pharma’s GLP-1/GLP-2 receptor dual agonist may have only managed at best an average 4.3% reduction in weight loss ...

While Eli Lilly and Novo Nordisk currently dominate the GLP-1 receptor agonist space, there are more than 50 candidates in ...

Patients who received CT-388 had an average placebo-adjusted weight loss of 18.8%. CT-388 is well tolerated with only mild to ...

Altimmune is developing pemvidutide, a dual agonist of GLP-1 and glucagon receptors, with promising phase 2 data already seen ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in ...

Individuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed ...

Ozempic, Trulicity and Mounjaro were first approved to treat diabetes, however, in the last three years, the FDA has approved ...